The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 6, 2016, Pages 1093-1104

  Valenti, Daniela ^a   de Bari, Lidia ^a   de Rasmo, Domenico ^a   Signorile, Anna ^b   Henrion Caude, Alexandra ^c,d   Contestabile, Andrea ^e   Vacca, Rosa Anna ^a  

^a CNR   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c IMAGINE INSTITUTE   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

AMPK; Down syndrome; Mitochondrial bioenergetics; Mitochondrial biogenesis; Nutraceuticals; PGC 1

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; EPIGALLOCATECHIN GALLATE; LACTIC ACID; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RESVERATROL; SIRTUIN 1;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOENERGY; CELL ENERGY; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; DENTATE GYRUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CONTENT; DOWN SYNDROME; HIPPOCAMPUS; IMMUNOBLOTTING; IN VITRO STUDY; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL RESPIRATION; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; UPREGULATION;

EID: 84962886227     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.03.003     Document Type: Article

References (81)

1. Carducci F., Onorati P., Condoluci C., Di Gennaro G., Quarato P.P., Pierallini A., Sarà M., Miano S., Cornia R., Albertini G. Whole-brain voxel-based morphometry study of children and adolescents with Down syndrome. Funct. Neurol. 2013, 28:19-28.
2. Hibaoui Y., Grad I., Letourneau A., Sailani M.R., Dahoun S., Santoni F.A., Gimelli S., Guipponi M., Pelte M.F., Béna F., Antonarakis S.E., Feki A. Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. EMBO Mol. Med. 2014, 6:259-277.
3. Contestabile A., Benfenati F., Gasparini L. Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome. Prog. Neurobiol. 2010, 91:1-22.
4. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., Schmidt C., Bronson R.T., Davisson M.T. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
5. Contestabile A., Greco B., Ghezzi D., Tucci V., Benfenati F., Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J. Clin. Invest. 2013, 123:348-361.
6. Lin R., Iacovitti L. Classic and novel stem cell niches in brain homeostasis and repair. Brain Res. 2015, (pii: S0006-8993(15)00325-X).
7. Fernandez F., Morishita W., Zuniga E., Nguyen J., Blank M., Malenka R.C., Garner C.C. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 2007, 10:411-413.
8. Deidda G., Parrini M., Naskar S., Bozarth I.F., Contestabile A., Cancedda L. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. Nat. Med. 2015, 21:318-326.
9. Kann O., Kovács R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 2007, 292:C641-C657.
10. Xavier J.M., Rodrigues C.M., Solá S. Mitochondria: major regulators of neural development. Neuroscientist 2015, 6. (pii: 1073858415585472).
11. Wakabayashi J., Zhang Z., Wakabayashi N., Tamura Y., Fukaya M., Kensler T.W., Iijima M., Sesaki H. The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice. J. Cell Biol. 2009, 186:805-816.
12. Valenti D., de Bari L., De Filippis B., Henrion-Caude A., Vacca R.A. Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome. Neurosci. Biobehav. Rev. 2014, 46:202-217.
13. Lee Y., Oh S.B., Park H.R., Kim H.S., Kim M.S., Lee J. Selective impairment on the proliferation of neural progenitor cells by oxidative phosphorylation disruption. Neurosci. Lett. 2013, 535:134-139.
14. Oruganty-Das A., Ng T., Udagawa T., Goh E.L., Richter J.D. Translational control of mitochondrial energy production mediates neuron morphogenesis. Cell Metab. 2012, 16:789-800.
15. Valenti D., Tullo A., Caratozzolo M.F., Merafina R.S., Scartezzini P., Marra E., Vacca R.A. Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylate kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy. Biochem. J. 2010, 431:299-310.
16. Valenti D., Manente G.A., Moro L., Marra E., Vacca R.A. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. Biochem. J. 2011, 435:679-688.
17. Kim H., Quon H.J., Kim J.A. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol. 2014, 2:187-195.
18. Abib R.T., Peres K.C., Barbosa A.M., Peres T.V., Bernardes A., Zimmermann L.M., Quincozes-Santos A., Fiedler H.D., Leal R.B., Farina M., Gottfried C. Epigallocatechin-3-gallate protects rat brain mitochondria against cadmium-induced damage. Food Chem. Toxicol. 2011, 49:2618-2623.
19. Bastianetto S., Ménarda C., Quirion R. Neuroprotective action of resveratrol. Biochim. Biophys. Acta 2015, 1852:1195-1201.
20. Bastianetto S., Krantic S., Chabot J.G., Quirion R. Possible involvement of programmed cell death pathways in the neuroprotective action of polyphenols. Curr. Alzheimer Res. 2011, 8:445-451.
21. Schaffer S., Asseburg H., Kuntz S., Muller W.E., Eckert G.P. Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria. Mol. Neurobiol. 2012, 46:161-178.
22. Ferretta A., Gaballo A., Tanzarella P., Piccoli C., Capitanio N., Nico B., Annese T., Di Paola M., Dell'Aquila C., De Mari M., Ferranini E., Bonifati V., Pacelli C., Cocco T. Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease. Biochim. Biophys. Acta 2014, 1842:902-915.
23. Gorlach S., Fichna J., Lewandowska U. Polyphenols as mitochondria-targeted anticancer drugs. Cancer Lett. 2015, 366:141-149.
24. De la Torre R., De Sola S., Pons M., Duchon A., de Lagran M.M., Farré M., Fitó M., Benejam B., Langohr K., Rodriguez J., Pujadas M., Charles Bizot J., Cuenca A., Jane N., Catuara S., Covas M.I., Blehaut H., Herault Y., Delabar J.M., Dierssen M. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol. Nutr. Food Res. 2014, 58:278-288.
25. Valenti D., De Rasmo D., Signorile A., Rossi L., de Bari L., Scala I., Graneseg B., Papa S., Vacca R.A. Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome. Biochim. Biophys. Acta 2013, 1832:542-552.
26. Vacca R.A., Valenti D. Green tea EGCG plus fish oil omega-3 dietary supplements rescue mitochondrial dysfunctions and are safe in a Down's syndrome child. Clin. Nutr. 2015, 34:783-784.
27. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006, 127:1109-1122.
28. Zhou X., Chen M., Zen X., Yang J., Deng H., Yi L., Mi M-t. Resveratrol regulates mitochondrial reactive oxygen species homeostasis through Sirt3 signaling pathway in human vascular endothelial cells. Cell Death Dis. 2014, 5.
29. Madhyastha S., Sekhar S., Rao G. Resveratrol improves postnatal hippocampal neurogenesis and brain derived neurotrophic factor in prenatally stressed rats. Int. J. Dev. Neurosci. 2013, 31:580-585.
30. Park E.J., Pezzuto J.M. The pharmacology of resveratrol in animals and humans. Biochim. Biophys. Acta 2015, 1852:1071-1113.
31. Kulkarni S.S., Cantó C. The molecular targets of resveratrol. Biochim. Biophys. Acta 2015, 1852:1114-1123.
32. Babu H., Cheung G., Kettenmann, Palmer T.D., Kempermann G. Enriched monolayer precursor cell cultures from micro-dissected adult mouse dentate gyrus yield functional granule cell-like neurons. PLoS One 2007, 2.
33. Babu H., Claasen j.H., Kannan S., Rünker A.E., Palmer T., Kempermann G. A protocol for isolation and enriched monolayer cultivation of neural precursor cells from mouse dentate gyrus. Front. Neurosci. 2011, 5:89.
34. Yang N.C., Ho W.M., Chen Y.H., Hu M.L. A convenient one-step extraction of cellular ATP using boiling water for the luciferin-luciferase assay of ATP. Anal. Biochem. 2002, 306:323-327.
35. Walz W., Mukerji S. Lactate production and release in cultured astrocytes. Neurosci. Lett. 1988, 86:296-300.
36. Bénit P., Goncalves S., Philippe Dassa E., Brière J.J., Martin G., Rustin P. Three spectrophotometric assays for the measurement of the five respiratory chain complexes in minuscule biological samples. Clin. Chim. Acta 2006, 374:81-86.
37. De Filippis B., Valenti D., de Bari L., De Rasmo D., Musto M., Fabbri A., Ricceri L., Fiorentini C., Laviola G., Vacca R.A. Mitochondrial free radical overproduction due to respiratory chain impairment in the brain of a mouse model of Rett syndrome: protective effect of CNF1. Free Radic. Biol. Med. 2015, 83:167-177.
38. LeBel C.P., Ischiropoulos H., Bondy S.C. Evaluation of the probe 2',7-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 1992, 5:227-231.
39. Fato R., Bergamini C., Leoni S., Lenaz G. Mitochondrial production of reactive oxygen species: role of complex I and quinone analogues. Biofactors 2008, 32:31-39.
40. Valenti D., de Bari L., Manente G.A., Rossi L., Mutti L., Moro L., Vacca R.A. Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells. Biochim. Biophys. Acta 2013, 1832:2085-2096.
41. Park H.R., Kong K.H., Yu B.P., Mattson M.P., Lee J. Resveratrol inhibits the proliferation of neural progenitor cells and hippocampal neurogenesis. J. Biol. Chem. 2012, 287:42588-42600.
42. Wagatsuma A., Kotake N., Mabuchi K., Yamada S. Expression of nuclear-encoded genes involved in mitochondrial biogenesis and dynamics in experimentally denervated muscle. J. Physiol. Biochem. 2011, 67:359-370.
43. Austin S., St-Pierre J. PGC1α and mitochondrial metabolism emerging concepts and relevance in ageing and neurodegenerative disorders. J. Cell Sci. 2012, 125:4963-4971.
44. Fernandez-Marcos P.J., Auwerx J. Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. Am. J. Clin. Nutr. 2011, 93:884S-890S.
45. Scarpulla R.C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev. 2008, 88:611-638.
46. Nieman D.C., Henson D.A., Maxwell K.R., Williams A.S., McAnulty S.R., Jin F., Shanely R.A., Lines T.C. Effects of quercetin and EGCG on mitochondrial biogenesis and immunity. Med. Sci. Sports Exerc. 2009, 41:1467-1475.
47. Pallàs M., Casadesús G., Smith M.A., Coto-Montes A., Pelegri C., Vilaplana J., Camins A. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr. Neurovasc. Res. 2009, 6:70-81.
48. Cantó C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20:98-105.
49. Wu Y., Li X., Zhu J.X., Xie W., Le W., Fan Z., Jankovic J., Pan T. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 2011, 19:163-174.
50. Gasparrini M., Giampieri F., Alvarez Suarez J.M., Mazzoni L., Forbes Hernandez T.Y., Quiles J.L., Bullon P., Battino M. AMPK as a new attractive therapeutic target for disease prevention: the role of dietary compounds. Curr. Drug Targets Jun 15 2015, (Epub ahead of print).
51. Chen D., Pamu S., Cui Q., Chan T.H., Dou Q.P. Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg. Med. Chem. 2012, 20:3031-3037.
52. Costa A.C., Scott-McKean J.J. Prospects for improving brain function in individuals with Down syndrome. CNS Drugs 2013, 27:679-702.
53. Xie W., Ramakrishna N., Wieraszko A., Hwang Y.W. Promotion of neuronal plasticity by (-)-epigallocatechin-3-gallate. Neurochem. Res. 2008, 33:776-783.
54. Park J., Song W.J., Chung K.C. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell. Mol. Life Sci. 2009, 66:3235-3240.
55. Guedja F., Lopes Pereirab P., Najasc S., Barallobrec M.J., Chaberta C., Soucheta B., Sebriee C., Verneyf C., Heraultb Y., Arbonesc M., Delabar J.M. DYRK1A: a master regulatory protein controlling brain growth. Neurobiol. Dis. 2012, 46:190-220.
56. Dierssen M., de Lagrán M.M. DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): a gene with dosage effect during development and neurogenesis. ScientificWorldJournal Jun 6 2006, 1911-1922.
57. Guedj F., Bianchi D.W., Delabar J.M. Prenatal treatment of Down syndrome: a reality?. Curr. Opin. Obstet. Gynecol. 2014, 26:92-103.
58. Stagni F., Giacomini A., Guidi S., Ciani E., Bartesaghi R. Timing of therapies for Down syndrome: the sooner, the better. Front. Behav. Neurosci. 2015, 9:265.
59. Smoliga J.M., Baur J.A., Hausenblas H.A. Resveratrol and health - a comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55:1129-1141.
60. Su B., Wang X., Bonda D., Perry G., Smith M., Zhu X. Abnormal mitochondrial dynamics-a novel therapeutic target for Alzheimer's disease?. Mol. Neurobiol. 2010, 41:87-96.
61. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60:748-766.
62. Cheng A., Hou Y., Mattson M.P. Mitochondria and neuroplasticity. ASN Neuro 2010, 2.
63. Rugarli E.I., Langer T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J. 2012, 31:1336-1349.
64. Bambrick L.L., Fiskum G. Mitochondrial dysfunction in mouse trisomy 16 brain. Brain Res. 2008, 1188:9-16.
65. Piccoli C., Izzo A., Scrima R., Bonfiglio F., Manco R., Negri R., Quarato G., Cela O., Ripoli M., Prisco M., Gentile F., Calì G., Pinton P., Conti A., Nitsch L., Capitanio N. Chronic pro-oxidative state and mitochondrial dysfunctions are more pronounced in fibroblasts from Down syndrome foeti with congenital heart defects. Hum. Mol. Genet. 2013, 22:1218-1232.
66. Rachidi M., Lopes C. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur. J. Paediatr. Neurol. 2008, 12:168-182.
67. Raveau M., Lignon J.M., Nalesso V., Duchon A., Groner Y., Sharp A.J., Dembele D., Brault V., Hérault Y. The App-Runx1 region is critical for birth defects and electrocardiographic dysfunctions observed in a Down syndrome mouse model. PLoS Genet. 2012, 8(2012).
68. Li H., Wang J., Wang P., Rao Y., Chen L. Resveratrol reverses the synaptic plasticity deficits in a chronic cerebral hypoperfusion rat model. J. Stroke Cerebrovasc. Dis. 2015, (pii: S1052-3057(15)00490-5).
69. Jäger S., Handschin C., St-Pierre J., Spiegelman B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12017-12022.
70. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434:113-118.
71. Teyssier C., Ma H., Emter R., Kralli A., Stallcup M.R. Activation of nuclear receptor coactivator PGC-1alpha by arginine methylation. Genes Dev. 2005, 19:1466-1473.
72. Cantó C., Gerhart-Hines Z., Feige J.N., Lagouge M., Noriega L., Milne J.C., Elliott P.J., Puigserver P., Auwerx J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
73. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13:1016-1023.
74. Menard C., Bastianetto S., Quirion R. Neuroprotective effects of resveratrol and epigallocatechin gallate polyphenols are mediated by the activation of protein kinase C gamma. Front. Cell. Neurosci. 2013, 7:281.
75. Torres-Pérez M., Tellez-Ballesteros R.I., Ortiz-López L., Ichwan M., Vega-Rivera N.M., Castro-García M., Gómez-Sánchez A., Kempermann G., Ramirez-Rodriguez G.B. Resveratrol enhances neuroplastic changes, including hippocampal neurogenesis, and memory in Balb/C mice at six months of age. PLoS One 2015, 10.
76. Del Rio D., Stewart A.J., Mullen W., Burns J., Lean M.E., Brighenti F., Crozier A. HPLC-MSn analysis of phenolic compounds and purine alkaloids in green and black tea. J. Agric. Food Chem. 2004, 52:2807-2815.
77. Hashim S.N., Schwarz L.J., Boysen R.I., Yang Y., Danylec B., Hearn M.T. Rapid solid-phase extraction and analysis of resveratrol and other polyphenols in red wine. J. Chromatogr. A. 2013, 1313:284-290.
78. Sakata Y., Zhuang H., Kwansa H., Koehler R.C., Doré S. Resveratrol protects against experimental stroke: putative neuroprotective role of heme oxygenase 1. Exp. Neurol. 2010, 224:325-329.
79. Martel F., Monteiro R., Calhau C. Effect of polyphenols on the intestinal and placental transport of some bioactive compounds. Nutr. Res. Rev. 2010, 23:47-64.
80. Sarma D.N., Barrett M.L., Chavez M.L., Gardiner P., Ko R., Mahady G.B., Marles R.J., Pellicore L.S., Giancaspro G.I., Low Dog T. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf. 2008, 31:469-484.
81. Sergides C., Chirilă M., Silvestro L., Pitta D., Pittas A. Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Exp. Ther. Med. 2016, 11:164-170.